

SPECIAL ISSUE INSIGHT

# Physiology of extracorporeal CO<sub>2</sub> removal



Luciano Gattinoni<sup>1\*</sup> , Silvia Coppola<sup>2</sup> and Luigi Camporota<sup>3</sup>

© 2022 The Author(s)

Extracorporeal CO<sub>2</sub> removal (ECCO<sub>2</sub>R) was introduced in 1977 to control arterial CO<sub>2</sub> tension and reduce ventilation [1], thus allowing lung rest in patients with acute respiratory failure (ARF) [2].

Its feasibility has been tested in a clinical trial [3], but clear evidence of benefit is lacking. Furthermore, a recent randomized study comparing standard lung protective ventilation versus an ultra-protective strategy with ECCO<sub>2</sub>R, in moderate-severe ARF, showed no difference in 90-day survival, but greater adverse events and fewer ventilator-free days in the ECCO<sub>2</sub>R arm [4]. Unfortunately, the relative contribution of ECCO<sub>2</sub>R on total CO<sub>2</sub> clearance and its effects on the natural lung are unexplored. Indeed, the CO<sub>2</sub> excretion from artificial and natural lungs is generally not measured, and the ventilatory strategy does not account for the physiological changes due to ECCO<sub>2</sub>R. In this brief report, we aim to describe the physiological basis of CO<sub>2</sub> removal, extensively studied in healthy animal models. To which extent these concepts might be directly translatable to pathological conditions will require further clinical studies. However, a reappraisal of the physiological basis of ECCO<sub>2</sub>R–natural lung interactions may clarify the rationale behind its clinical application.

## Physical–chemical characteristics of ECCO<sub>2</sub>R

The key concept underlying low-flow ECCO<sub>2</sub>R is that due to the high CO<sub>2</sub> content in the venous blood (45–50 ml/100 ml at venous PCO<sub>2</sub> = 45 mmHg), the metabolically produced CO<sub>2</sub> (~150–200 ml/min) may be

theoretically removed from 400 to 500 ml of blood. The amount of CO<sub>2</sub> removed—for a given sweep gas flow—increases linearly with the artificial lung surface area and the PCO<sub>2</sub> of the pre-membrane blood; and logarithmically with the blood flow [5]. High ventilation/perfusion ratio of the artificial lung is required for an adequate CO<sub>2</sub> removal with a post-membrane PCO<sub>2</sub> as low as 5–10 mmHg [6].

## Artificial and natural lung interactions

### Physiology

The ECCO<sub>2</sub>R was first studied in healthy lambs [1]. The key-finding was that the sum of VCO<sub>2</sub> of the natural and artificial lungs remained unchanged when ECCO<sub>2</sub>R was increased. Consequently, the spontaneously breathing animals maintained a normal arterial PCO<sub>2</sub>. When 100% of the metabolic VCO<sub>2</sub> was removed by the membrane lung, it was possible to maintain the animals “apneic” with normal PCO<sub>2</sub>, while the oxygenation was maintained through an intratracheal 100% oxygen inflow matching the oxygen consumption (“apneic oxygenation”) [7] (Fig. 1). A similar linear decrease in minute ventilation proportional to the ECCO<sub>2</sub>-R was described in spontaneously breathing patients with ARF [8].


### Gas exchange

1. While the amount of oxygen exchanged through the natural lung is unmodified by ECCO<sub>2</sub>R, as the oxygen added extracorporeally is negligible, the VCO<sub>2</sub> eliminated by the natural lung decreased in proportion to the VCO<sub>2</sub> eliminated through ECCO<sub>2</sub>R. Therefore, the respiratory quotient (RQ = VCO<sub>2</sub>/VO<sub>2</sub>) decreases. The change in RQ modifies the alveolar PO<sub>2</sub> which is function of both FiO<sub>2</sub> and the PCO<sub>2</sub>/RQ ratio, according to the alveolar gas equation. Therefore, during ECCO<sub>2</sub>R, despite a constant FiO<sub>2</sub>, the alveolar and arterial PO<sub>2</sub> may decrease due to a decrease in RQ [7, 9]). The cardiovascular effects of ECCO<sub>2</sub>R will depend on the net effect on

\*Correspondence: gattinoniluciano@gmail.com

<sup>1</sup> Department of Anesthesiology, Medical University of Göttingen, University Medical Center Göttingen, Robert Koch Straße 40, 37075 Göttingen, Germany

Full author information is available at the end of the article



the pulmonary vascular resistance resulting from the reduction in alveolar and arterial PO<sub>2</sub> and hypercapnia (increase in pulmonary arterial pressure); and the PO<sub>2</sub> and PCO<sub>2</sub> in the mixed venous blood which results from the extracorporeal support.

2. During apnea, the alveolar gas composition is affected by the nitrogen concentration in the artificial lung, to which the alveolar nitrogen equilibrates. If the nitrogen in the artificial is lower than the natural lung, i.e., if the fraction of oxygen delivered through the membrane lung is greater than FiO<sub>2</sub>, the natural lung will be progressively depleted of nitrogen [7]. This may favor reabsorption atelectasis in the regions of the natural lung with low ventilation/perfusion ratio, increasing the pulmonary units instability [10]. This phenomenon was proved experimentally in conditions of apnea but may theoretically occur regionally during clinical conditions.

#### Lung mechanics

As tidal volume is reduced, the mean transpulmonary pressure decreases, and the lung tends to collapse. Experimental data on healthy animals show that the lung volume is halved after 24 h of apnea at 5 cmH<sub>2</sub>O of positive end-expiratory pressure (PEEP) [7]. To prevent this phenomenon in healthy lungs, two alternatives are possible:

1. Raising the mean airway pressure. It must be noted, however, that a PEEP of ~20–25 cmH<sub>2</sub>O may be required to preserve lung volumes in lambs during apnea [11], as well as to keep the lungs fully open in patients with acute respiratory distress syndrome (ARDS) [12]. These pressures are generally associated to important hemodynamic consequences, worse fluid balance and kidney function.
2. Adding an adequate short inflation “sigh”. In healthy animals, it is sufficient to add one sigh of 10–12 ml/kg every 90 s to preserve lung volumes [13]. The role of sigh, in this context, is not to increase gas exchange, but only to preserve lung-volume [14, 15].

#### Discrepancies between physiology and actual current ECCO<sub>2</sub>R applications

##### Gas exchange

The effects of the decrease in respiratory quotient (RQ) during ECCO<sub>2</sub>R is usually ignored in clinical practice. However, this phenomenon may be relevant when FiO<sub>2</sub> is reduced, as during weaning. In this phase, the low RQ may cause hypoxemia, which may be incorrectly interpreted as caused by derecruitment.

The reabsorption atelectasis resulting from the lung de-nitrogenization when using 100% oxygen through the artificial lung may occur in the ARDS lung due higher

prevalence of low ventilation/perfusion regions, the higher weight of the lung, and the loss of diaphragmatic tone which favors the formation of compression atelectasis. This problem may be prevented by ventilating the artificial and natural lungs with the same oxygen fraction.

### Lung mechanics

During “ultraprotective” lung strategy and ECCO<sub>2</sub>R, PEEP is usually increased, and plateau pressure decreased, while the respiratory rate is maintained constant. Actually, in the intervention group of the REST trial, the mechanical ventilation was very similar to the controls [4]. The potential advantages of ECCO<sub>2</sub>R on mechanical ventilation were, therefore, not exploited, leading only to an increase in the complications associated to ECCO<sub>2</sub>R and anticoagulation. During ultraprotective ventilation strategy, three conditions may promote atelectasis: (a) lower tidal volume and plateau pressure; (b) lung de-nitrogenization when using 100% oxygen through the artificial lung; c) PEEP levels insufficient to keep the lung open ( $\geq 20$ –25 cmH<sub>2</sub>O). A combination of low frequency plus the addition of sighs and equal FiO<sub>2</sub> in the natural and artificial lungs—as suggested by physiology—could enhance lung protection and prevent progressive lung collapse.

### Take-home message

Understanding the physiology of ECCO<sub>2</sub>R and the consequent modification in the natural lung is necessary to optimize the ventilatory management and design stronger future clinical trials.

### Author details

<sup>1</sup> Department of Anesthesiology, Medical University of Göttingen, University Medical Center Göttingen, Robert Koch Straße 40, 37075 Göttingen, Germany. <sup>2</sup> Department of Anesthesiology and Intensive Care, ASST Santi Paolo e Carlo Hospital, University of Milan, Milan, Italy. <sup>3</sup> Department of Adult Critical Care, Health Centre for Human and Applied Physiological Sciences, Guy's and St Thomas' NHS Foundation Trust, London, UK.

### Acknowledgements

We would like to thank Sartorius AG (Göttingen, Germany) and Massimo Fileni for an unrestricted grant for lung injury-related research towards the Department of Anesthesiology of Göttingen University Medical Center.

### Funding

Open Access funding enabled and organized by Projekt DEAL.

### Declarations

### Conflicts of interest

LG reports a consultancy for General Electrics and SIDAM. He also receives lecture fees from Estor and Mindray.

### Ethical approval

Not requested.

### Open Access

This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing,

adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc/4.0/>.

### Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 20 May 2022 Accepted: 12 July 2022

Published: 25 August 2022

### References

- Kolobow T, Gattinoni L, Tomlinson TA, Pierce JE (1977) Control of breathing using an extracorporeal membrane lung. *Anesthesiology* 46:138–141. <https://doi.org/10.1097/0000542-197702000-00012>
- Gattinoni L, Agostoni A, Pesenti A, Pelizzola A, Rossi GP, Langer M, Vesconi S, Uziel L, Fox U, Longoni F, Kolobow T, Damia G (1980) Treatment of acute respiratory failure with low-frequency positive-pressure ventilation and extracorporeal removal of CO<sub>2</sub>. *Lancet* (London, England) 2:292–294. [https://doi.org/10.1016/s0140-6736\(80\)90237-8](https://doi.org/10.1016/s0140-6736(80)90237-8)
- Combes A, Fanelli V, Pham T, Ranieri VM (2019) Feasibility and safety of extracorporeal CO(2) removal to enhance protective ventilation in acute respiratory distress syndrome: the SUPERNOVA study. *Intensive Care Med* 45:592–600. <https://doi.org/10.1007/s00134-019-05567-4>
- McNamee JJ, Gillies MA, Barrett NA, Perkins GD, Tunnicliffe W, Young D, Bentley A, Harrison DA, Brodie D, Boyle AJ, Millar JE, Szakmany T, Bannard-Smith J, Tully RP, Agus A, McDowell C, Jackson C, McAuley DF (2021) Effect of lower tidal volume ventilation facilitated by extracorporeal carbon dioxide removal vs standard care ventilation on 90-day mortality in patients with acute hypoxemic respiratory failure: the REST randomized clinical trial. *JAMA* 326:1013–1023. <https://doi.org/10.1001/jama.2021.13374>
- Kolobow T, Gattinoni L, Tomlinson T, White D, Pierce J, Iapichino G (1977) The carbon dioxide membrane lung (CDML): a new concept. *Transactions* 23:17–21. <https://doi.org/10.1097/00002480-19770230-00005>
- Duscio E, Cipulli F, Vasques F, Collino F, Rapetti F, Romitti F, Behnemann T, Niewenhuys J, Tonetti T, Pasticci I, Vassalli F, Reupke V, Moerer O, Quintel M, Gattinoni L (2019) Extracorporeal CO<sub>2</sub> removal: the minimally invasive approach, theory, and practice. *Crit Care Med* 47:33–40. <https://doi.org/10.1097/ccm.0000000000003430>
- Kolobow T, Gattinoni L, Tomlinson T, Pierce JE (1978) An alternative to breathing. *J Thorac Cardiovasc Surg* 75:261–266
- Marcolin R, Mascheroni D, Pesenti A, Bombino M, Gattinoni L (1986) Ventilatory impact of partial extracorporeal CO<sub>2</sub> removal (PECOR) in ARF patients. *ASAIO Trans* 32:508–510. <https://doi.org/10.1097/00002480-198609000-00025>
- Gattinoni L, Kolobow T, Tomlinson T, White D, Pierce J (1978) Control of intermittent positive pressure breathing (IPPB) by extracorporeal removal of carbon dioxide. *Br J Anaesthesia* 50:753–758. <https://doi.org/10.1093/bja/50.8.753>
- Dantzker DR, Wagner PD, West JB (1974) Proceedings: instability of poorly ventilated lung units during oxygen breathing. *J Physiol* 242:72p
- Gattinoni L, Iapichino G, Kolobow T (1979) Hemodynamic, mechanical and renal effects during “apneic oxygenation” with extracorporeal carbon dioxide removal, at different levels of intrapulmonary pressure in lambs. *Int J Artif Organs* 2:249–253
- Cressoni M, Chiumello D, Algieri I, Brioni M, Chiurazzi C, Colombo A, Colombo A, Crimella F, Guanziroli M, Tomic I, Tonetti T, Luca Vergani G, Carlesso E, Gasparovic V, Gattinoni L (2017) Opening pressures and

- 
- atelectrauma in acute respiratory distress syndrome. *Intensive Care Med* 43:603–611. <https://doi.org/10.1007/s00134-017-4754-8>
13. Gattinoni L, Kolobow T, Tomlinson T, Iapichino G, Samaja M, White D, Pierce J (1978) Low-frequency positive pressure ventilation with extracorporeal carbon dioxide removal (LFPPV-ECCO2R): an experimental study. *Anesthesia Analgesia* 57:470–477. <https://doi.org/10.1213/0000539-197807000-00018>
  14. Pelosi P, Cadringer P, Bottino N, Panigada M, Carrieri F, Riva E, Lissoni A, Gattinoni L (1999) Sigh in acute respiratory distress syndrome. *Am J Respir Crit Care Med* 159:872–880. <https://doi.org/10.1164/ajrccm.159.3.9802090>
  15. Mauri T, Foti G, Fornari C, Grasselli G, Pinciroli R, Lovisari F, Tubiolo D, Volta CA, Spadaro S, Rona R, Rondelli E, Navalesi P, Garofalo E, Knafelj R, Gorjup V, Colombo R, Cortegiani A, Zhou JX, D'Andrea R, Calamai I, Vidal González Á, Roca O, Grieco DL, Jovaisa T, Bampalis D, Becher T, Battaglini D, Ge H, Luz M, Constantin JM, Ranieri M, Guerin C, Mancebo J, Pelosi P, Fumagalli R, Brochard L, Pesenti A (2021) Sigh in patients with acute hypoxemic respiratory failure and ARDS: the PROTECTION pilot randomized clinical trial. *Chest* 159:1426–1436. <https://doi.org/10.1016/j.chest.2020.10.079>